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We read with great interest the recently published study by Mutlak et al [1]. The authors 
conducted prospective observational study with aim to assess capability of the multiple electrode 
aggregomatry (MEA) to reflect the extent of cardiopulmonary bypass (CPB) associated platelet 
dysfunction [1]. Study cohort consisted of patients that underwent either hypothermic or 
normothermic CPB. Adenosine di-phosphate test induced platelet aggregation (ADP test) was 
considered as a primary endpoint. Put briefly, platelet function as assessed using MEA ADP test 
reflected the time-dependent extent of CPB-induced platelet dysfunction [1]. Study by Mutlak et 
al [1] certainly adds to the current knowledge; however some methodological considerations 
should inevitably be addressed.  
In cardiac surgery patients, disturbances in platelet function predominantly root from either 
preoperative antiplatelet drugs administration or are acquired during CPB pump run. In our 
opinion, clear distinction between these two predominant causes of platelet dysfunction should be 
made, as holds great practical value.  
This study [1] is of great value, however confirms findings that are well known so far[1]. Such 
studies should be focused towards the gaps in our knowledge pertaining to this specific issue. 
First of all, the relationship between platelet dysfunction and bleeding outcomes/transfusion 
requirements should be validated in prospective multicentric trials [2]. Our working group has 
recently published studies evaluating predictability of bleeding complications by using MEA 
both preoperatively [3] and intraoperatively [4]. Even though we reported positive results with 
calculated receiver operating curve cut-off values, the fact is that the literature reveals 
controversial data on predictability of bleeding complications using platelet function testing  [5-
7]. Therefore, further efforts to elucidate this field are warranted. 
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Despite emerging evidence on a) widespread variability in platelet inhibitory response to 
antiplatelet therapy and b) the effects of CPB and hypothermia on platelet function, the fact is 
that use of numerous platelet function testing devices in heterogeneously designed studies 
hamper pooling of the evidence which in turn results in the lack of consensus on platelet 
reactivity level that would be associated with bleeding events in different time points pertaining 
to the cardiac surgery procedures. In their study [1], authors considered patients as eligible if their 
ex vivo arachidonic acid and ADP-induced platelet aggregation were within normal reference 
values after the induction of anesthesia [1]. Preoperative administration of antiplatelet drugs was 
considered as exclusion criterion [1]. We understand that authors wanted to exclude the possible 
underlying effects of preoperatively administered antiplatelet drugs in order to elucidate more 
precisely the role of CPB itself on platelet function. However, in the real-life, there is growing 
number of patients that are scheduled for complex procedures with antiplatelet drugs being 
administered for some reason in close proximity to surgery. We need answers how to manage 
these patients at particular risk for excessive bleeding. In our opinion, the influence of preexisting 
antiplatelet therapy on platelet function should be weighed against the influence of CPB on 
platelet function. Also, it should be elucidated whether the underlying platelet dysfunction caused 
by preoperatively administered antiplatelet drugs influences dynamics of platelet function 
changes during CPB? Authors should consider possibility to conduct a new “historically 
controlled” study where the findings obtained on patients exposed preoperatively to antiplatelet 
drugs would be compared to findings obtained in the present study [1]. The study by Mutlak et al 
[1] certainly adds to the current knowledge, however, further research on this field is warranted in 
order to provide further refinements in hemostatic management of cardiac surgery patients. So 
far, valuable algorithm provided by Weber et al [8], has shown that hemostatic therapy based on 
point-of-care testing may reduce patient exposure to allogeneic blood products and provide 
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significant benefits with respect to clinical outcomes[8]. Nowadays, evolution of hemostatic 
management warrants further refinements in hemostatic management. There are several areas of 
gaps in our knowledge related to hemostatic management that should be addressed in upcoming 
studies:  
1) The role of antiplatelet drugs is not clearly understood. Current guidelines on preoperative 
antiplatelet administration/discontinuation management rely on “one-size-fits-all” strategy 
despite emerging evidence on huge individual variability in platelet inhibitory response to 
antiplatelet drugs. Using drug specific platelet function tests, the exact cut-off values that increase 
odds for bleeding complications should be defined and antiplatelet drug 
administration/discontinuation management should be adjusted accordingly. The impact of 
preoperatively administered antiplatelet drugs on bleeding complications should not be 
underestimated [9,10]. Huge variability in individual platelet inhibitory response to antiplatelet 
drugs deserves attention and clear distinction between patients who have pronounced platelet 
inhibition from those who have high degree of residual platelet reactivity should be made and 
preoperative administration/discontinuation management should be adjusted accordingly. That 
would be a significant shift towards personalized management in patient care for which we may 
assume that would probably result in more favorable clinical outcomes.   
2) Next generation of hemostatic algorithms should be developed. These should encompass 
preoperative, intraoperative and postoperative time points with respective measures. Preoperative 
part should pertain to risk stratification and measures to prevent bleeding risk (i.e. personalized 
preoperative antiplatelet therapy management). Intraoperative part should, as concept, remain 
very similar to present one published by Weber et al[8], albeit some refinements are required,  
particularly in defining triggers for transfusion administration. Cut-off values that delineate 
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bleeding tendency and that are validated in studies recruiting the population of particular interest 
(ie. Cardiac surgery patients) should be used in transfusion management rather than “normal 
range” values. Apart from the fact that “normal range” values are usually derived from healthy 
volunteers, the fact is that cut-of values defined by ROC analysis [11] are by statistical chances 
more precisely related to some endpoints with the best sensitivity/specificity ratio comparing to 
values expressed as range. If defined in prospective studies and applied to similar patients, cut-of 
values may the most reliably direct transfusion practice and are easy to follow in clinical practice 
since decision making is based on binary decisions (Simplified decision making: i.e. below/above 
cut-of value  – do/do not transfuse). 
Finally, we congratulate authors on timely and elegant study. Moreover, we call for prospective 
multicentric study that would be conducted by centers with expertise in this particular field. The 
aim of such a study would be to re-visit the hemostatic management algorithms and provide new 
concepts consisted of bundle of hemostatic strategies encompassing measures in pre- , intra- and 
postoperative period. 
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